摘要
目的探究蚁利肝胶囊联合替诺福韦对乙肝肝硬化患者肝功能及肝纤维化的影响。方法选取2015年5月—2018年3月于河北省沧州市传染病医院收治的患者90例,按照随机数字表法分为对照组和观察组,各45例。对照组给予替诺福韦治疗,观察组给予蚁利肝胶囊联合替诺福韦治疗,比较两组临床疗效、实验室检查指标。结果观察组的临床总有效率高于对照组,差异有统计学意义(P<0.05)。两组治疗后血清总胆红素(TBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)水平均低于治疗前,凝血酶原时间(PT)短于治疗前,且观察组TBIL、ALT、AST水平均低于对照组,PT短于对照组(P<0.05)。两组治疗后透明质酸酶、血层粘连蛋白、Ⅳ型胶原、Ⅲ型前胶原水平均低于治疗前,且观察组低于对照组(P<0.05)。观察组治疗23、46周的HBV-DNA转阴率均高于对照组,差异有统计学意义(P<0.05)。结论蚁利肝胶囊联合替诺福韦对乙肝肝硬化患者的临床疗效显著,可保护肝细胞活性,显著改善患者肝脏功能,减轻肝脏纤维化,提高患者生活质量,值得临床推广应用。
Objective To explore the effect of Yiligan Capsules combined with Tenofovir on liver function and liver fibrosis in patients with hepatitis B cirrhosis.Methods Ninety patients from May 2015 to March 2018 in Cangzhou Infectious Disease Hospital of Hebei Province were selected and divided into control group and observation group according to random number table method,45 cases in each group.Control group was treated with Tenofovir,and observation group was given Yiligan Capsules combined with Tenofovir.Clinical efficacy and laboratory examination indexes of two groups were compared.Results Total clinical effective rate of observation group was higher than that of control group(P<0.05).After treatment,serum total bilirubin(TBil),alanine aminotransferase(ALT),aspartate aminotransferase(AST)levels of two groups were lower than those before treatment,prothrombin time(PT)of two groups was shorter than that before treatment,and the levels of TBil,ALT and AST in observation group were lower than those in control group,and PT in observation group was shorter than that in control group(P<0.05).After treatment,the levels of hyaluronidase,blood laminin,typeⅣcollagen and typeⅢprocollagen in two groups were lower than those before treatment,and those in observation group were lower than those in control group(P<0.05).The negative conversion rate of HBV-DNA in observation group was higher than that in control group at 23 and 46 weeks of treatment,and the differences were statistically significant(P<0.05).Conclusion Yiligan Capsules combined with Tenofovir has significant clinical effect on patients with hepatitis B cirrhosis,it can protect the activity of liver cells,significantly improve the liver function,reduce liver fibrosis and improve the quality of life of patients,which is worthy of clinical application.
作者
王洁冰
唐平阳
徐会选
WANG Jiebing;TANG Pingyang;XU Huixuan(Department of Hepatology,Cangzhou Infectious Disease Hospital,Hebei Province,Cangzhou061000,China)
出处
《中国医药导报》
CAS
2020年第28期147-150,共4页
China Medical Herald
基金
河北省中医药管理局课题(2019309)。
关键词
蚁利肝胶囊
乙肝肝硬化
肝功能
肝纤维化
临床疗效
Yiligan Capsules
Hepatitis B cirrhosis
Liver function
Liver fibrosis
Clinical effect
